Radiant Biotherapeutics

radiantbio.com
Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Series A
Fund:
Compass Rose
An antibody platform company developing multi-valent, multi-specific therapeutics, called Multabodies, to deliver transformative therapies for patients.

Related news

Radiant Biotherapeutics reaches milestone to advance its new class of therapeutics against complex cancers

FACIT seeded start-up, Radiant Biotherapeutics (“Radiant”), announced the closing of Series A financing to advance the company’s proprietary multi-specific therapeutics for patients with complex cancers. Radiant’s unique multi-valent antibody platform, called Multabody™, generates best-in-class antibodies with superior potency against multiple target sites implicated in heterogenous diseases such as cancers and can potentially improve patient outcome. Read More

FACIT backed Radiant Biotherapeutics announces closing of $8M seed round for cancer therapies

Emerging from stealth mode, Radiant's financing enables the Company to continue rapidly advancing its Multabodies that have application across multiple diseases including cancer. Read More

FACIT Features: Radiant Biotherapeutics, next-gen biotech developing multabody therapies for cancer

October 21, 2021 – Radiant received a seed investment from FACIT’s Compass Rose Oncology Fund. Read More

FACIT generates $1.5 billion in follow-on investment

FACIT announced $1.5 billion in follow-on investment attracted to its portfolio of cancer biotechnology start-ups in Ontario, a significant milestone for life science commercialization in Canada. Read More

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.